News
Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.
Zacks Investment Research on MSN5h
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback